Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-03
2011-05-03
Hui, San-ming (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07935718
ABSTRACT:
The present invention relates to the use of compounds that enhance H3-histamine receptor activity, or activation (e.g. H3-histamine receptor agonists) for the treatment of dyskinesia. The compounds are particularly useful for treating dyskinesia associated with parkinsonian therapy.
REFERENCES:
patent: 4767778 (1988-08-01), Arrang
patent: 4816456 (1989-03-01), Summers
patent: 5091428 (1992-02-01), Pascal
patent: 5463074 (1995-10-01), Shih
patent: 5821259 (1998-10-01), Theoharides
patent: 5965571 (1999-10-01), Hutchinson
patent: 6136559 (2000-10-01), Lovenberg et al.
patent: 6316475 (2001-11-01), Bennani
patent: 6455536 (2002-09-01), Brotchie
patent: 6740659 (2004-05-01), Brotchie
patent: 2004/0057956 (2004-04-01), Brotchie et al.
patent: 2004/0067956 (2004-04-01), Brotchie
patent: 2005/0009856 (2005-01-01), Brotchie
patent: 2005/0261282 (2005-11-01), Crossman et al.
patent: 2006/0069039 (2006-03-01), Crossman et al.
patent: 98/44118 (1998-10-01), None
patent: 00 20011 (2000-04-01), None
Ingram N.A.W, Newgreen D.B.; “The Use of Tacrine for Tardive Dyskinesia”; American Journal of Psychiatry, vol. 140, No. 31, 1983, pp. 16-29, XP000989784.
JL Juncos et al; “Cholinergic Strategies in T Tourette Synorome: An Open-Label Trial of Tacrine Hydrochloride” Neurology, US, Lippincott Williams & Wilkins, Philadelphia, vol. 48, No. 3, Mar. 1, 1997, p. A397, XP002087141.
Chiavegatto, Silvana et al; “Histamine and Spontaneous Motor Activity: Biphasic Changes, Receptors Involved and Participation of the Striatal Dopamine System” LIFE SCI, 1998, 62(20), 1875-1888, XP000989725.
Sakai n. et al; “Effects of Thioperamide, A Histamine H3 Receptor Antagonish, on Locomotor Activity and Brain Histamine Content in MAST Cell-Deficient W/WV Mice”; Life Sciences, GB, Peramon Press, Oxford, vol. 48, No. 25, 1991, pp. 2397-2404, XP002042695.
Itoh, Yoshinori et al; “Neuronal Histamine Inhibits Methamphetamine-Induced Locomotor Hyperactivity in Mice”; Neurosci, LETT, 1984, 48(3), 305-9, XP000989775.
Huotari M et al; “Effects of Histamine H-3-Ligand on the Levodopa-Induced Turning Behavior of Hemiparkinsonian Rates”; Parkinsonism & Related Disorders, Jul. 2000, vol. 6, No. 3, pp. 159-164; Publisher: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX 5 1GB, Oxon, England, ISSN: 1353-8020; XP000989734.
Hill M P et al; “Histamine H3 Receptors Modulate Dopamine D1 Receptor-Dependent Locomotion in the Reserpine-Treated Rat Model of Parkinson's Disease”; Society for Neuroscience Abstracts, vol. 25, No. 1-2, 1999, p. 171; XP000989999.
Schunack and Stark, “Design of Histamine H3-Receptor Agonists and Antagonists”, European Journal of Drug Metabolism and Pharmacokinetics 3:173-178 (1994).
Lovenberg et al, “Cloning of Rat Histamine H3 Receptor Reveals Distinct Species Pharmacological Profiles”, The Journal of Pharmacology and Experimental Therapeutics 293(3):771-778 (2000).
Leurs et al, “Therapeutic potential of histamine H3 receptor agonists and antagonists”, TiPS 19:177-183 (1998).
Timmerman, “Histamine H3 ligands: just pharmacological tools or potential therapeutic agents?”, Journal of Medicinal Chemistry 33(1):4-11 (1990).
Leurs et al, “Molecular Pharmacological Aspects of Histamine Receptors”, Pharmac. Ther. 66(3):413-463 (1995).
Hill, “Distribution, Properties, and Functional Characteristics of Three Classes of Histamine Receptor”, Pharmacological Reviews 42(1):45-83 (1990).
Kathmann et al, “Nordimaprit, homodimaprit, clobenpropit and imetit: affinities for H3 binding sites and potencies in a functional H3 receptor model”, Arch Pharmacol. 348: 498-503 (1993).
Lipp et al, “Synthesis, absolute configureation, stereoselectivity, and receptor selectivity of (.alpha.R,.beta.S)-.alpha.,.beta.-dimethylhistamine. A novel highly potent histamine H3 receptor agonist”, J. Med. Chem. 35(23):4434-4441 (1992).
Hill et al, “Levetiracetam Potentiates the Antidyskinetic Action of Amantadine in the 1-Methy1-4-pheny1-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson's Disease”, The Journal of Pharmacology and Experimental Therapeutics 310(1):386 (2004).
Henry et al, “μ- and δ-Opioid Receptor Antagonists Reduce Levodopa-Induced Dyskinesia in the MPTP-Lesioned Primate Model of Parkinson's Disease”, Experimental Neurology 171:139-146 (2001).
Danysz et al, “Aminoadamantanes as NMDA Receptor Antagonists and Antiparkinsonian Agents—Preclinical Studies”, Neuroscience and Biobehavioral Reviews 21(4):455-468 (1997).
Allen (1998) European Journal of Pharmacology 361:261-268, “Agonist and antagonist effects of histamine H receptor ligands on 3 5-HT receptor-mediated ion currents in NG108-15 cells”.
Arrang, et al. (1985) European Journal of Pharmacology 117:109-114, “Stereoselectivity of the Histamine H3-Presynaptic Autoreceptor”.
De Esch, et al. (1999) Journal of Medicinal Chemistry 42(7):1115-1122, “Characterization of the Binding Site of the Histamine H3Receptor. 1. Various Approaches to the Synthesis of 2-(1H-Imidazol-4-yl)cyclopropylamine and Histaminergic Activity of (1R,2R)- and (1S,2S)-2-(1H-Imidazol-4-yl)-cyclopropylamine”.
Gomez-Ramirez, et al. (2006) Movement Disorders 21(6):839-846, “Histamine H3 Receptor Agonists Reduce L-Dopa-Induced Chorea, but Not Dystonia, in the MPTP-Lesioned Nonhuman Primate Model of Parkinson's Disease”.
International Search Report, PCT/GB00/04046, dated Mar. 27, 2001.
Jablonowski, et al. (2003) J. Med. Chem. 46:3957-3960, “The First Potent and Selective Non-Imidazole Human Histamine H4 Receptor Antagonists”.
Kathmann, et al. (1993) Naunyn-Schmiedeberg's Arch Pharmacol 348:498-503, “Nordimaprit, homodimaprit, clobenpropit and imetit: affinities for H3binding sites and potencies in a functional H3receptor model”.
Krause, et al. (May 12, 2007) “Medicinal chemistry of histamine H3receptor agonists” Website [Online] Available Web Site: http://www.sciencedirect.com/science?—ob=ArticleURL&—udi=B8GX3-4NPX535-D&—user=10&—coverDate=12%2F31%2F1998&—rdoc=1&—fmt=high&—orig=search&—origin=search&—sort=d&—docanchor=&view=c&—searchStrId=1518064147&—rerunOrigin=google&—acct=C000050221&—version=1&—urlVersion=0&—userid=10&md5=53 8d5dfcf6f4d31213049be9d0c4b6ea&searchtype=a; Last Update: Unknown; Accessed on: Oct. 28, 2010.
Leurs, et al. (1995) British Journal of Pharmacology 116:2135-2321, “Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed”.
Leurs, et al. (1995) Pharmac. Ther. 66(3):413-463, “Molecular Pharmacological Aspects of Histamine Receptors”.
Leurs, et al. (1998) TiPS 19:177-183, “Therapeutic potential of histamine H3receptor agonists and antagonists”.
Lipp, et al. (1992) J. Med. Chem. 35(23):4434-4441, “Synthesis, absolute configuration, stereoselectivity, and receptor selectivity of (αR,βS)-α,β-dimethylhistamine, a novel highly potent histamine H3receptor agonist”.
Lovenberg, et al. (2000) The Journal of Pharmacology and Experimental Therapeutics 293(3):771-778, “Cloning of Rat Histamine H3Receptor Reveals Distinct Species Pharmacological Profiles”.
Nguyen, et al. (2001) Molecular Pharmacology 59:427-433, “Discovery of a Novel Member of the Histamine Receptor Family”.
Nickel, et al. (2001) Br J Pharmacol. 132(8):1665-1672, “Novel histamine H3-receptor antagonists and partial agonists with a non-aminergic structure”.
Shih, et al. (1995) J. Med. Chem. 38:1593-1599, “A Novel Pyrrolidin
Brotchie Jonathan
Crossman Alan
Hill Michael
Hui San-ming
Motac Neuroscience Limited
Swanson & Bratschun L.L.C.
LandOfFree
Treatment of dyskinesia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of dyskinesia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of dyskinesia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2635775